Satellite Sessions

All Satellite Sessions are open sessions and all are welcome to attend. The Conference Registration Desk will be open until 15:00 on Thursday, 10 October for those who wish to attend the Thursday satellite session. Name badges are REQUIRED to access the upper levels of the International Convention Center (CCIB) where all satellites will take place. 


Monday, 7 October

Room #


Session Title

Room 122

08:30 - 10:30

Catalyzing a Health Innovation System that Works for All

 Download Session Agenda [1]
Host Institution: Salud por Derecho – Right to Health Foundation

Session Overview: The idea that it is necessary to reform the current biomedical R&D system gains greater support each day. Furthermore, Horizon 2020 and the WHO commitments to implement recommendations that will solve some of the structural failures in the way in which  research and development of medical technologies is organized are a clear step forward. How will these programs and advances affect the AIDS vaccine research field and what opportunities do they present?


This session will present the Catalytic Project, an initiative that is engaging the scientific community in this process of change. We will analyze the problem from the researchers’ perspective and the possible implementation of some already existing proposals to guide R&D so that it responds to the real health needs of individuals, ensuring affordable access to biomedical products and facilitating innovation and scientific progress.


In addition, the field of HIV/AIDS is particularly interesting to develop this reflection, since HIV vaccines are technologies of global interest, not only for impoverished countries, and there are many initiatives, such as public-private partnerships and public research organizations dedicated to this work.



Room 124

08:30 - 10:30

Supporting HIV Vaccine R&D Using the CHVI R&D Alliance Virtual Community
Host Institutions: Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO)

Session Overview: The Canadian HIV Vaccine Initiative (CHVI) is a commitment between the Government of Canada and the Bill & Melinda Gates Foundation which supports and amplifies Canadian and global HIV vaccine research and development efforts. The CHVI Research and Development Alliance Coordinating Office (ACO) has created the CHVI R&D Alliance Virtual Community (Alliance VC) to build collaborations and augment capacity building. This Internet‐based community allows HIV vaccine researchers to communicate, collaborate and share information. The site provides a secure virtual meeting space for hosting groups, document creation and editing tools, teleconferences and webinars, resource materials, and a Canadian researcher database. This session will describe the CHVI, and demonstrate the site's features, tools, and confidential committee workspaces. A hands‐on workshop will show participants how to start using the Alliance VC. Participants are encouraged to bring their computers. For more information, visit


Room 123

08:30 - 11:30

Antibody and NK Recognition of HIV-1 Infected Cells
Host Institution: Duke University Medical Center

Session Overview: There is a relevant body of literature indicating that Natural Killer (NK) cells play an important role in the control of HIV-1 infection. It is still unclear which HIV-1 envelope structures may impact recognition of infected cells by NK-mediated activity. In the past years, progress has been made in defining structures of the envelope glycoproteins, their assembly on the surface of infectious virions, and how they may be similar to envelope structures on the surface of infected cells. However, it is unclear whether more than one envelope structural configuration is present on virions and/or on the cell surface, as initially suggested by Moore et al. (35), or if only envelope trimers are present, as recently suggested by Haim et al. (36). The variety of the different envelope structures present on the surface of the infected cells will highly impact their recognition by the NK effector populations. In addition to the structure of the envelope on the surface of infected cells, HIV-1 can affect the complex interactions of inhibitory and activating receptors with their ligands on the surface of infected cells. Both, the composition of envelope on the surface of infected cells and modulation of regulatory receptors ultimately affect the ability of NK cells to recognize the HIV-1 infected cells by both direct and indirect mechanisms. The direct mechanisms are most likely driven by virus protein such as Vpr, which induces ligands to the activation receptor, NKG2D. In addition to the activation receptors the ability of NK cells to respond to HIV-infected cells include the ability to recognize infected cells based on downregulation of HLA-A and -B molecules as well as interactions between KIR2DL inhibitory receptors and HLA-C, which remains on the surface of infected cells. The indirect mechanism mainly involves the cooperation between humoral immunity and the NK cells in the immune response termed Antibody Dependent Cellular Cytotoxicity (ADCC), where antibody (Ab) directed against HIV-1 antigens can recognize infected cells and recruit NK cells via binding of their Fc region to the NK Fcγ-Receptors.


Room 130

09:00 - 10:30

Speaking Science to the Public

 Download Session Agenda [2]
Host Institutions: AVAC, Global HIV Vaccine Enterprise

Session Overview: Whether you're a bench scientist, a clinician or community educator, you've had to explain complicated science to the public. Come learn how to talk about complex scientific concepts in presentations and to the media – or just explain to your neighbors what it is you do. This interactive session will help you learn to synthesize information into the key messages that your audience can understand, remember and take action on. Bring your difficult-to-explain scientific concepts and fears about the media for discussion. You'll learn how to package your information and gain confidence in front of colleagues and reporters. 


Room 129

10:30 - 13:30

Major Bottlenecks in HIV Vaccine Development: The Light at the End of the Tunnel
Host Institutions: European Commission + Universite Pierre et Marie Curie (FR) 

Session Overview: Despite significant investments and global research efforts over the last 25 years, an effective HIV vaccine is currently not in sight. This and major failures in recent phase II and III clinical trials should lead to fundamental questioning of current models and development paradigms. HIV vaccine research has always been a priority in the European Union's activities and it has been supported throughout the Framework Programmes for Research and Innovation (FP) as well as through the European and Developing Countries Clinical Trials Partnership (EDCTP), which supports capacity building and advance clinical trials for HIV, TB and malaria in sub-Saharan Africa. Aspects of HIV vaccine design will be examined in the light of the questions above. 


Room 130

11:00 - 12:00

Capturing Participant Information for Mucosal Sampling: an Investigator's Guide

 Download Session Agenda [3]
Host Institutions: Global HIV Vaccine Enterprise, NIAID, the HIV Mucosal Immunology Group

Session Overview: Mucosal immunity and mucosal sampling are increasingly a focus for HIV vaccine development. We will introduce a guidance document being developed by cross-Network experts, the HIV Mucosal Immunology Group, and the Global HIV Vaccine Enterprise as a resource  to help Investigators develop participant questionnaires that best match study-specific objectives of clinical trials conducting sampling from gut or genital mucosa.  The guide compiles key participant characteristics that can affect mucosal immunity and are essential for proper interpretation and cross-trial comparison of mucosal data. We will review project history, present a case study, and demonstrate use of the guide.


Room 123

12:00 - 15:00

Structure and Antigenicity of Soluble, Cleaved (SOSIP) HIV-1 gp140 Trimers

 Download Session Agenda [4]

Host Institutions: Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID)

Session Overview: This session will present exciting new data on cleaved soluble gp140 trimers based on the subtype A HIV-1 BG505 sequence.  These highly stable trimers are excellent antigenic mimics of the native, virion-associated Env spike and display epitopes for broadly neutralizing Abs while occluding non-neutralizing epitopes in contrast to uncleaved gp140 trimers of various genotypes that adopt irregular and heterogeneous, non-native structures.  Of central importance, we will describe two highly concordant high-resolution structures (<6Å) of these cleaved soluble trimers derived by cryo-electron microscopy and X-ray crystallography.


Room 130

12:30 - 13:30

From Bench to Clinic: A Researchers Guide to Move Vaccine Candidates into Trials

 Download Session Agenda [5]
Host Institutions: IAVI, UK HIV Vaccine Consortium, Global HIV Vaccine Enterprise

Session Overview: Taking a candidate vaccine into a Phase I study, even if well characterized in preclinical study, is a complex multi-step process that requires comprehensive knowledge and understanding of a large number of interrelated issues. This satellite will bring together experts on regulatory, manufacturing and product development to discuss how the transition can be done smoothly. It will also present a new interactive webtool, which gives investigators an overview of key steps in this process, describes the relevant expertise required at each step, and provides estimates of the typical timelines and costs, based on three potential types of vaccine products.  


Room 124

13:30 - 15:30

Enabling Technologies and Methods for HIV Vaccine Research and Clinical Trials

 Download Session Agenda [6]
Host Institutions: Fraunhofer Institute for Biomedical Engineering FhG IBMT, UniversitatPompeuFabra

Session Overview: Infections with HIV still represent a major human health problem worldwide and a vaccine is the only long-term option to fight efficiently against this virus. Standardized assessments of HIV-specific immune responses in vaccine trials are essential for prioritizing vaccine candidates in pre-clinical and clinical stages of development. Therefore, harmonization and validation of laboratory techniques, the use of consistent reagents and the cryopreservation of laboratory specimens are of main importance.


Room 127+

13:30 - 15:30

AIDS Vaccine Research at the Crossroads: How to Adapt to a New Prevention Agenda

 Download Session Agenda [7]

[8] Presentation: the Kitchen Sink, Glenda Gray, Perinatal HIV Research Institute 

[9] Presentation: Developing AIDS Vaccine, Policy Perspectives, Margie McGlynn, IAVI

 Presentation: The HIV Prevention Research Landscape, Catherine Hankins, Amsterdam Institute for Global Health


Host Institutions: International AIDS Vaccine Initiative; AVAC: Global Advocacy for HIV Prevention; Amsterdam Institute for Global Health and Development

Session Overview: In the wake of recent developments in the AIDS vaccine field, AIDS Vaccine 2013 attendees will have an opportunity to reflect on recent lessons learned from clinical trials and discovery science, and review them in the context of current and planned research efforts. These include two planned efficacy trials as follow up to RV144; the launch of a number of new vaccine approaches in early clinical trials; and increased understanding of how to design vaccines that can elicit broadly neutralizing antibodies. The direction of vaccine research, however, is also being shaped by progress in the response to HIV/AIDS and policies regarding the broader health and development arena. Evolving standards for HIV treatment and prevention, and a new (post-2015, post-Millennium Development Goals) agenda for global health, development and research will have implications for the way research efforts are moving forward. This session will take a critical look at this comprehensive set of dynamics, aiming to identify gaps and priorities for the field and issues to be addressed for future AIDS vaccine development efforts.


Room 130

14:00 - 15:00

Strategic Directions for Therapeutic HIV Vaccine Research

 Download Session Agenda [10]
Host Institution: AVAC, TAG, Bill & Melinda Gates Foundation, Global HIV Vaccine Enterprise

Session Overview: The therapeutic vaccine field has seen a revival in the recent years, largely associated with the cure agenda. The Enterprise, together with AVAC, the Treatment Action Group, and the Bill & Melinda Gates Foundation, organized a meeting to discuss the state of the field and to provide strategic recommendations for future developments. The satellite will update on the issues discussed at the meeting, including: scientific gaps in therapeutic vaccine development; opportunities for scientific coordination and synergies between the areas of therapeutic vaccine, preventive vaccine, the treatment optimization, and cure research; and ethical and regulatory considerations related to trial design, including choice of clinical endpoints.


Thursday, 10 October

Room #


Session Title

Room 124+

15:00 - 17:00

Meta-Analysis of HVTN Efficacy Studies with Adenovirus Vectors
Host Institution: Fred Hutchinson Cancer Research Center and the HIV Vaccine Trials Network

Session Overview: The HVTN has conducted a series of efficacy trials involving recombinant Adenovirus type 5 containing vaccines. Despite high rates of immunogenicity, none of the trials were shown to reduce the primary or secondary endpoints of reducing HIV acquisition or post acquisition viral load. The populations studied as well as the insert genes utilized differed in each of the regions. For example, the Step study (HVTN 502/504) was conducted in Clade B regions of the world using a homologous combination of the MRK-Ad5 vector. The Phambili study (HVTN 503) used the same regimen as in the Step study but in South Africa where Clade C predominantly circulates. HVTN 505 used a heterologous regimen of a DNA prime and Ad5 boost vaccine from the NIH/Vaccine Research Center. This session will present overviews and updates of the individual trials and a meta-analysis of the three trials to prompt discussion regarding the findings and future directions of Adenovirus based vaccines for HIV and other diseases.